Evidence map›Paper›PMID 29532791›Full record

ReviewMolecular psychiatry2018

Mechanisms of ketamine action as an antidepressant.

P Zanos, T D Gould

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Molecular psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 525 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
525citing papers in PubMed, 14 pooled it
55.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05181527 phase4completednot on this mapstarted 2022, after this paper: background citation

Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder: A Randomized, Group Sequential, Adaptive Design, Controlled Clinical Trial

TypeinterventionalSponsorAll India Institute of Medical Sciences, BhubaneswarRan2022 to 2023Enrolled60ConditionsMajor Depressive DisorderArmsSelective Serotonin Reuptake Inhibitors, Dextromethorphan, Placebo
NCT07120477 phase4suspendednot on this mapstarted 2026, after this paper: background citation

Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)

TypeinterventionalSponsorUniversity of Sao PauloRan2026 to 2029Enrolled468ConditionsSuicide Prevention, Ketamine, Crisis Response PlanArmsIntravenous Esketamine, Crisis Response Planning intervention (structures safety planning)
3 · Its place in the literature

Who cites it

525 citing papers in PubMed, 14 syntheses or guidelines pooled it, 1,063 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Quantitative evaluation of multiple treatment regimens for treatment-resistant depression.The international journal of neuropsychopharmacology · 2025
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Ketamine in fibromyalgia: a systematic review.Advances in rheumatology (London, England) · 2024
    Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

465 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

P ZanosDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
T D GouldDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
University of Maryland, Baltimore · US

Funding

Therapeutic Efficacy of Ketamine Metabolites for Depression TreatmentR01MH107615 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOULD, TODD D · 2016 to 2025
$7.2M
NIMH NIH HHS R01 MH107615
6 · The paper itself

Abstract

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions. Although this finding has been met with enthusiasm, ketamine's widespread use is limited by its abuse potential and dissociative properties. Recent preclinical research has focused on unraveling the molecular mechanisms underlying the antidepressant actions of ketamine in an effort to develop novel pharmacotherapies, which will mimic ketamine's antidepressant actions but lack its undesirable effects. Here we review hypotheses for the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, inhibition of NMDARs localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor activation. We also discuss links between ketamine's antidepressant actions and downstream mechanisms regulating synaptic plasticity, including brain-derived neurotrophic factor (BDNF), eukaryotic elongation factor 2 (eEF2), mechanistic target of rapamycin (mTOR) and glycogen synthase kinase-3 (GSK-3). Mechanisms that do not involve direct inhibition of the NMDAR, including a role for ketamine's (R)-ketamine enantiomer and hydroxynorketamine (HNK) metabolites, specifically (2R,6R)-HNK, are also discussed. Proposed mechanisms of ketamine's action are not mutually exclusive and may act in a complementary manner to exert acute changes in synaptic plasticity, leading to sustained strengthening of excitatory synapses, which are necessary for antidepressant behavioral actions. Understanding the molecular mechanisms underpinning ketamine's antidepressant actions will be invaluable for the identification of targets, which will drive the development of novel, effective, next-generation pharmacotherapies for the treatment of depression.

Indexed as

AnimalsAntidepressive AgentsBrain-Derived Neurotrophic FactorDepressionDepressive DisorderGlycogen Synthase Kinase 3HumansInterneuronsKetamineNeuronal PlasticityNeuronsReceptors, N-Methyl-D-AspartateSynapsesAntidepressive AgentsBrain-Derived Neurotrophic FactorGlycogen Synthase Kinase 3KetamineNR2B NMDA receptorReceptors, N-Methyl-D-Aspartate

Identifiers

PMID29532791
PMCPMC5999402
OpenAlexW2790275773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.